How do we identify and measure value for patients with rare diseases?
Authors: Annie Kennedy and Joff Masukawa. Rare diseases impact 1 in 10 Americans, and over 400 million people worldwide. The current development and FDA approval process can cost hundreds of millions of dollars – and take an average of 15 years – to develop one therapy. For the 30% of children diagnosed with a rare […]
Exploring Patient Heterogeneity and Diversity in Treatment Responses
Author: Jennifer Bright, MPA Everyone hopes for a COVID vaccine so our lives can return to normal. Yet, we know that even if clinical trials prove a vaccine’s effectiveness, our society will still have to endure a long process of distribution. I’m personally willing to wait for a vaccine for healthcare workers, the elderly, and […]
Tackling Hard Questions in Value
Author: Jennifer Bright, MPA, Executive Director, IVI For decades, we’ve known that untreated or poorly treated Major Depressive Disorder (MDD) is an enormous burden on individual patients, our health care system, and our society. Despite having this knowledge, there is much work to do in order to support and optimize cost-effective care for patients suffering […]
Looking Ahead to 2021: Let’s Really Make 2021 the Year of the Patient
Author: Jennifer Bright, MPA, Executive Director, IVI The promise of a new year offers an opportunity to recall our best moments in 2020 (surely there are a few!) and get excited for what’s ahead. For IVI, I’ve been thinking about the accomplishments not just in 2020, but in the three years since I joined this […]